How Cancers Escape Immune Destruction and Mechanisms of Action for the New Significantly Active Immune Therapies: Helping Nonimmunologists Decipher Recent Advances-Reference-Cited by-同舟云学术

How Cancers Escape Immune Destruction and Mechanisms of Action for the New Significantly Active Immune Therapies: Helping Nonimmunologists Decipher Recent Advances

Published:2016-02-01 Issue:2 Volume:21 Page:233-243
ISSN:1083-7159
Container-title:The Oncologist
language:en
Short-container-title:

Author:

Messerschmidt Jonathan L.¹²,Prendergast George C.¹²,Messerschmidt Gerald L.¹²³

Affiliation:

1. a Lankenau Institute for Medical Research, Wynnewood, Pennsylvania, USA

2. b Lankenau Medical Center, Wynnewood, Pennsylvania, USA

3. c Clinical Research Center, Lankenau Institute for Medical Research, Wynnewood, Pennsylvania, USA

Abstract

Abstract With the Food and Drug Administration and other worldwide regulatory authorities’ approval of ipilimumab (Yervoy), sipuleucel-T (Provenge), nivolumab (Opdivo), and pembrolizumab (Keytruda), oncologic therapy has now moved into noncancer cell targets within the immune system. For many nonimmunologists, understanding how these vastly different therapies work to improve survival, like no other therapies have in the past, is a challenge. The present report reviews the normal function of the immune system, how cancers escape the normal immune system, and how these new therapies improve immune system reactions against cancers.

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1634/theoncologist.2015-0282

Reference77 articles.

1. Sipuleucel-T immunotherapy for castration-resistant prostate cancer;Kantoff;N Engl J Med,2010

2. Improved survival with ipilimumab in patients with metastatic melanoma;Hodi;N Engl J Med,2010

3. Nivolumab in previously untreated melanoma without BRAF mutation;Robert;N Engl J Med,2015

4. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer;Brahmer;N Engl J Med,2015

5. FDA expands approved use of Opdivo in advanced lung cancer. Opdivo demonstrates survival benefit in squamous and non-squamous non-small cell lung cancer;FDA News Release,2015

Cited by 71 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Decoding the Mystery of Blood Cancer: Cause, Diagnosis, and Management;Current Cancer Therapy Reviews;2025-01

2. Changing the Landscape of Solid Tumor Therapy from Apoptosis-Promoting to Apoptosis-Inhibiting Strategies;Current Issues in Molecular Biology;2024-05-28

3. Hydrogel-based drug delivery systems for synergistic chemo/hyperthermia therapy of cancer: A comprehensive review;Journal of Drug Delivery Science and Technology;2024-05

4. E-cadherin re-expression: Its potential in combating TRAIL resistance and reversing epithelial-to-mesenchymal transition;Gene;2024-05

5. The opposite role of lactate dehydrogenase a (LDHA) in cervical cancer under energy stress conditions;Free Radical Biology and Medicine;2024-03